-
Bright Horizons Family Solutions (BFAM) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY25 Guidance
-
Bright Horizons (BFAM) PT Lowered to $112 at UBS
-
Bright Horizons (BFAM) PT Lowered to $138 at BMO Capital
-
Bright Horizons Family Solutions (BFAM) Tops Q2 EPS by 6c; offers guidance
-
Jefferies Downgrades Bright Horizons (BFAM) to Hold
-
These 2 sectors are under-owned, Barclays says and advises where to invest
-
Bright Horizons Family Solutions (BFAM) Tops Q1 EPS by 13c ; Offers Guidance
-
Bright Horizons (BFAM) PT Raised to $146 at BMO Capital as 'BUCA Strength Continues'
-
Bright Horizons (BFAM) PT Raised to $148 at Jefferies
-
Bright Horizons (BFAM) PT Raised to $145 at Baird
-
Bright Horizons Family Solutions (BFAM) Tops Q4 EPS by 8c, Offers Guidance
-
Bright Horizons (BFAM) PT Lowered to $100 at Morgan Stanley
-
Bright Horizons (BFAM) PT Lowered to $130 at UBS
-
Baird Upgrades Bright Horizons (BFAM) to Outperform
-
BMO Capital Upgrades Bright Horizons (BFAM) to Outperform
-
Bright Horizons (BFAM) PT Raised to $140 at Baird
-
Jefferies Reiterates Buy Rating on Bright Horizons (BFAM)
-
Bright Horizons (BFAM) PT Raised to $162 at Goldman Sachs
-
Bright Horizons Family Solutions (BFAM) Tops Q3 EPS by 5c, Misses on Revenue; Offers FY24 Guidance
-
3 ways to gain stock market exposure to the fertility theme
-
Bright Horizons (BFAM) PT Raised to $122 at BMO Capital
-
Bright Horizons Family Solutions (BFAM) Tops Q2 EPS by 15c, Beats on Revenue; Offers FY24 Guidance
-
These stocks offer you exposure to rising demand for fertility treatment – Barclays

